NSCLC non-metastatic

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 21/06/2022)

PACIFIC-4 (AstraZeneca) (Stage IA3 or IB or IIA)
International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515).